RAPID MICRO BIOSYSTEMS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.9456 USD | -0.46% |
|
+6.25% | +27.78% |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 440 | 47.45 | 31.38 | 40.47 | - | - |
| Enterprise Value (EV) 1 | 246.5 | -61.19 | -60.67 | -16.34 | 12.5 | -30.57 |
| P/E ratio | -2.7 x | -0.79 x | -0.61 x | -0.84 x | -0.89 x | -2.36 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 18.9 x | 2.77 x | 1.39 x | 1.49 x | 1.09 x | 0.79 x |
| EV / Revenue | 10.6 x | -3.57 x | -2.69 x | -0.6 x | 0.34 x | -0.6 x |
| EV / EBITDA | -5.39 x | 1.01 x | 1.13 x | 0.36 x | -0.29 x | 0.8 x |
| EV / FCF | -4,236,673 x | 937,315 x | - | - | - | - |
| FCF Yield | -0% | 0% | - | - | - | - |
| Price to Book | 2 x | 0.29 x | 0.27 x | 0.46 x | 1.01 x | 1.23 x |
| Nbr of stocks (in thousands) | 41,353 | 41,994 | 42,409 | 42,793 | - | - |
| Reference price 2 | 10.64 | 1.130 | 0.7400 | 0.9456 | 0.9456 | 0.9456 |
| Announcement Date | 3/4/22 | 3/3/23 | 3/1/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 23.23 | 17.13 | 22.52 | 27.08 | 37.2 | 51.23 |
| EBITDA 1 | - | -45.7 | -60.38 | -53.46 | -45.94 | -43.73 | -38.06 |
| EBIT 1 | - | -47.23 | -63.22 | -56.56 | -48.89 | -46.86 | -41.48 |
| Operating Margin | - | -203.31% | -368.99% | -251.18% | -180.52% | -125.98% | -80.96% |
| Earnings before Tax (EBT) 1 | - | - | -61.38 | - | -45.2 | -43.6 | - |
| Net income 1 | -42.54 | -78.03 | -60.81 | -52.47 | -46.27 | -44.59 | -39.16 |
| Net margin | - | -335.88% | -354.91% | -232.99% | -170.86% | -119.86% | -76.43% |
| EPS 2 | -23.72 | -3.940 | -1.430 | -1.220 | -1.130 | -1.067 | -0.4000 |
| Free Cash Flow | - | -58.18 | -65.29 | - | - | - | - |
| FCF margin | - | -250.43% | -381.06% | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 3/22/21 | 3/4/22 | 3/3/23 | 3/1/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 6.899 | 5.208 | 4.16 | 3.86 | 4.739 | 4.374 | 5.035 | 5.002 | 6.145 | 6.337 | 5.5 | 6.2 | 7.1 | 8.2 | - |
| EBITDA 1 | -11.74 | -14.11 | -14.44 | -13.39 | -16.15 | -16.4 | -14.11 | -14.28 | -13.67 | -11.39 | -12 | -11.5 | -11.5 | -10.4 | - |
| EBIT 1 | -12.12 | -14.56 | -15 | -14.07 | -16.89 | -17.26 | -14.87 | -15.05 | -14.45 | -12.19 | -12.7 | -12.2 | -12.2 | -11.1 | - |
| Operating Margin | -175.72% | -279.49% | -360.55% | -364.61% | -356.32% | -394.6% | -295.37% | -300.96% | -235.13% | -192.33% | -230.91% | -196.77% | -171.83% | -135.37% | - |
| Earnings before Tax (EBT) 1 | -24.97 | - | -14.91 | -13.7 | -16.33 | -16.44 | -13.88 | - | - | - | -12 | -11.5 | -11.4 | -10.4 | - |
| Net income 1 | -24.99 | -14.6 | -14.93 | -13.09 | -16.34 | -16.45 | -13.89 | -14.02 | -13.39 | -11.17 | -12 | -11.5 | -11.4 | -10.4 | - |
| Net margin | -362.18% | -280.43% | -358.89% | -339.12% | -344.78% | -376.02% | -275.81% | -280.21% | -217.93% | -176.3% | -218.18% | -185.48% | -160.56% | -126.83% | - |
| EPS 2 | -0.7100 | -0.3500 | -0.3500 | -0.3100 | -0.3800 | -0.3900 | -0.3200 | -0.3300 | -0.3100 | -0.2600 | -0.2900 | -0.2867 | -0.2767 | -0.2767 | -0.2700 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/11/21 | 3/4/22 | 5/10/22 | 8/12/22 | 11/10/22 | 3/3/23 | 5/5/23 | 8/4/23 | 11/3/23 | 3/1/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - |
| Net Cash position 1 | - | 193 | 109 | 92.1 | 56.8 | 28 | 71 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow | - | -58.2 | -65.3 | - | - | - | - |
| ROE (net income / shareholders' equity) | - | -156% | -31.6% | -37.2% | -48.9% | -82.1% | -69.5% |
| ROA (Net income/ Total Assets) | - | - | -28.2% | - | - | - | - |
| Assets 1 | - | - | 215.9 | - | - | - | - |
| Book Value Per Share 2 | - | 5.330 | 3.900 | 2.740 | 2.040 | 0.9400 | 0.7700 |
| Cash Flow per Share | - | - | - | - | - | - | - |
| Capex | - | 3.22 | 6.74 | - | - | - | - |
| Capex / Sales | - | 13.85% | 39.34% | - | - | - | - |
| Announcement Date | 3/22/21 | 3/4/22 | 3/3/23 | 3/1/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
0.9456
USD
Average target price
5.25
USD
Spread / Average Target
+455.20%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +27.78% | 40.47M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- RPID Stock
- Financials Rapid Micro Biosystems, Inc.
